AKAOQ - Week In Review: invoX A Sino Biopharm Company To Pay $161 Million To Acquire F-Star
- invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies.
- Xuanzhu Biopharm of Shandong out-licensed China rights for two anti-infectives to Shanghai SPH New Asia Pharma in a $66 million agreement.
- AstraZeneca will set up its sixth China regional headquarters in Qingdao, a port city in eastern Shandong province, forming a rare disease innovation center, a life science innovation park and an industry fund.
For further details see:
Week In Review: invoX, A Sino Biopharm Company, To Pay $161 Million To Acquire F-Star